| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.002 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.002 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |